ESMO 2026: Merck’s Kelun-partnered ADC hits the ‘Goldilocks zone,’ VP says

At the European Society for Medical Oncology meeting this weekend, Merck will showcase three late-stage trials of its Kelun-Biotech–partnered TROP2-directed antibody sac-TMT that VP of Chemistry Alan Northrup says gets the payload release “just right.”